"UPMC Passavant - McCandless is a hospital located in Pittsburgh.Visit our website to learn more about the conditions we treat and the services we offer. Schedule your appointment today. UPMC is committed to protecting our communities from the spread of COVID-19. We continue to require people who come to any UPMC facility to wear a facemask that covers their nose and mouth and to practice other preventative efforts like social distancing, even if fully vaccinated."

During the past decade, UPMC Passavant Hospital conducted 78 clinical trials. In the 10-year time frame, 78 clinical trials started and 37 clinical trials were completed, i.e. on average, 47.4% percent of trials that started reached the finish line to date. In the past 5 years, 30 clinical trials started and 33 clinical trials were completed. i.e. 110% of trials that started reached the finish line.

Out of the total clinical trials conducted in "UPMC Passavant Hospital" #1 sponsor was "National Cancer Institute (NCI)" with 41 trials, followed by "SWOG Cancer Research Network" with 16 trials sponsored, "Alliance for Clinical Trials in Oncology" with 15 trials sponsored, "ECOG-ACRIN Cancer Research Group" with 8 trials sponsored and "NRG Oncology" with 8 trials sponsored. Other sponsors include 13 different institutions and companies that sponsored additional 18 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "UPMC Passavant Hospital" #1 collaborator was "National Cancer Institute (NCI)" with 54 trials as a collaborator, "NRG Oncology" with 16 trials as a collaborator, "Canadian Cancer Trials Group" with 7 trials as a collaborator, "Radiation Therapy Oncology Group" with 2 trials as a collaborator and "Astellas Pharma US, Inc." with 1 trials as a collaborator. Other collaborators include 7 different institutions and companies that were collaborators in the rest 17 trials.

According to Clinical.Site data, the most researched conditions in "UPMC Passavant Hospital" are "Recurrent Squamous Cell Lung Carcinoma" (8 trials), "Stage IV Squamous Cell Lung Carcinoma AJCC v7" (7 trials), "Stage IIIA Breast Cancer" (6 trials), "Invasive Breast Carcinoma" (5 trials) and "Recurrent Lung Non-Small Cell Carcinoma" (5 trials). Many other conditions were trialed in "UPMC Passavant Hospital" in a lesser frequency.

Most popular intervention types in "UPMC Passavant Hospital" are "Drug" (85 trials), "Other" (63 trials), "Biological" (39 trials), "Procedure" (34 trials) and "Radiation" (27 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (35 trials), "Quality-of-Life Assessment" (25 trials), "Cisplatin" (18 trials), "Computed Tomography" (18 trials) and "Carboplatin" (17 trials). Other intervention names were less common.

The vast majority of trials in "UPMC Passavant Hospital" are 87 trials for "All" genders, 14 trials for "Female" genders and 5 trials for "Male" genders.

Currently, there are NaN active trials in "UPMC Passavant Hospital". 1 are not yet recruiting, 29 are recruiting, 46 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 23 completed trials in UPMC Passavant Hospital, 4 suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in UPMC Passavant Hospital, 0 "Phase 1" clinical trials were conducted, 51 "Phase 2" clinical trials and 60 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 6 trials that are defined as “Not Applicable".